• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Imunon Inc.

    8/13/25 6:29:02 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMNN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Imunon, Inc.

    (Name of Issuer)


    Common stock, par value $0.01 per share

    (Title of Class of Securities)


    15117N602

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    15117N602


    1Names of Reporting Persons

    Ayrton Capital LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    15117N602


    1Names of Reporting Persons

    Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    15117N602


    1Names of Reporting Persons

    Waqas Khatri
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Imunon, Inc.
    (b)Address of issuer's principal executive offices:

    997 Lenox Drive, Suite 100, Lawrenceville, NEW JERSEY, 08648.
    Item 2. 
    (a)Name of person filing:

    (i) Ayrton Capital LLC; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B; and (iii) Waqas Khatri
    (b)Address or principal business office or, if none, residence:

    (i) Ayrton Capital LLC, 55 Post Rd West, 2nd Floor Westport, CT 06880; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, Suite #7 Grand Pavilion Commercial Centre, 802 West Bay Road, Grand Cayman, P.O. Box 10250, Cayman Islands; and (iii) Waqas Khatri 55 Post Rd West, 2nd Floor Westport, CT 06880
    (c)Citizenship:

    (i) Ayrton Capital LLC: United States; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: Cayman Islands; and (iii) Waqas Khatri: United States
    (d)Title of class of securities:

    Common stock, par value $0.01 per share
    (e)CUSIP No.:

    15117N602
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Ayrton Capital LLC: 2,000; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 2,000; and (iii) Waqas Khatri: 2,000. Represents 2,000 shares of Common Stock issuable on the exercise of certain warrants (the "Warrants") and conversion of certain convertible notes (the "Notes") held by the Reporting Persons. The issuable shares of Common Stock related to the exercise of the Warrants is subject to a 9.99% beneficial ownership blocker. The shares reported herein represent Common Stock of Imunon, Inc. (the "Issuer") held by Alto Opportunity Master Fund, SPC- Segregated Master Portfolio B, a Cayman Islands exempted company (the "Fund"). The Fund is a private investment vehicle for which Ayrton Capital LLC, a Delaware limited liability company (the "Investment Manager"), serves as the investment manager. Waqas Khatri serves as the managing member of the Investment Manager (all of the foregoing, collectively, the "Reporting Persons").
    (b)Percent of class:

    The percentages below are based on 17,541,732 shares of Common Stock of the Issuer that were outstanding as of May 16, 2025 held by the Reporting Persons. The amount of shares outstanding was based upon a statement in the Issuer's Form S-1/A filed on May 19, 2025. For the sake of clarity, the holdings of the Reporting Persons reported herein are as of June 30, 2025, and are based on reported amounts prior to the Issuer's reverse stock split in July 2025. (i) Ayrton Capital LLC: 0.01%; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 0.01%; and (iii) Waqas Khatri: 0.01%.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (i) Ayrton Capital LLC: 2,000; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 2,000; and (iii) Waqas Khatri: 2,000

     (ii) Shared power to vote or to direct the vote:

    (i) Ayrton Capital LLC: 0; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 0; and (iii) Waqas Khatri: 0

     (iii) Sole power to dispose or to direct the disposition of:

    (i) Ayrton Capital LLC: 2,000; Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 2,000; Waqas Khatri: 2,000

     (iv) Shared power to dispose or to direct the disposition of:

    (i) Ayrton Capital LLC: 0; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 0; (iii) Waqas Khatri: 0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Ayrton Capital LLC
     
    Signature:/s/ Waqas Khatri
    Name/Title:Waqas Khatri / Managing Member
    Date:08/13/2025
     
    Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B
     
    Signature:/s/ Waqas Khatri
    Name/Title:Waqas Khatri / Director
    Date:08/13/2025
     
    Waqas Khatri
     
    Signature:/s/ Waqas Khatri
    Name/Title:Waqas Khatri
    Date:08/13/2025
    Get the next $IMNN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMNN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dentzer James E was granted 3,318 shares (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    8/6/25 4:37:44 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Pellizzari Christine A was granted 2,248 shares (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    8/6/25 4:35:18 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Braun Donald P was granted 2,040 shares, increasing direct ownership by 120% to 3,747 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    8/6/25 4:33:13 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Braun Donald P bought $29,480 worth of shares (25,000 units at $1.18), increasing direct ownership by 4,188% to 25,597 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    1/28/25 4:18:24 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Lindborg Stacy bought $24,500 worth of Imunon Common Stock (25,000 units at $0.98), increasing direct ownership by 10% to 264,166 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    8/16/24 8:03:50 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman of Board Tardugno Michael H bought $25,750 worth of Imunon Common Stock (25,000 units at $1.03), increasing direct ownership by 8% to 353,346 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    8/16/24 8:01:30 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

    Investors are reminded that Shareholders of record as of August 7, 2025, will receive a 15% stock dividend payment LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, earlier today reported financial results for the three-month and six-month periods ended June 30, 2025, and highlighted recent business updates, including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer and the introduction of a 15% stock dividend payment to shareholders. The following is a summary of remarks by Imunon's President and

    8/5/25 4:00:00 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

    Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study of IMNN-001 for treatment of newly diagnosed advanced ovarian cancer Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today reported financial results for the three-month and six-month periods ended June 30, 2025, and highlighted recent business updates, including progress in advancing Phase 3 clinical development of i

    8/5/25 8:00:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

    Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the first patient has been dosed in the pivotal Phase 3 OVATION 3 Study evaluating the Company's lead candidate, IMNN-001, for the treatment of women with newly diagnosed advanced ovarian cancer. The first patient was dosed by Melanie K. Bergman, M.D., FACOG, Gynecologic Oncologist with Providence Medical Group at Providence Health in Spokane, Washington. "IMNN-001 represents a potentially t

    7/30/25 8:05:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Financials

    Live finance-specific insights

    View All

    IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

    Investors are reminded that Shareholders of record as of August 7, 2025, will receive a 15% stock dividend payment LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, earlier today reported financial results for the three-month and six-month periods ended June 30, 2025, and highlighted recent business updates, including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer and the introduction of a 15% stock dividend payment to shareholders. The following is a summary of remarks by Imunon's President and

    8/5/25 4:00:00 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

    Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study of IMNN-001 for treatment of newly diagnosed advanced ovarian cancer Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today reported financial results for the three-month and six-month periods ended June 30, 2025, and highlighted recent business updates, including progress in advancing Phase 3 clinical development of i

    8/5/25 8:00:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

    LAWRENCEVILLE, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. ET on Tuesday, August 5, 2025 to discuss financial results for the second quarter ended June 30, 2025 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy, including progress in advancing the IMNN-001 development program in a Phase 3 clinical trial in advanced ovarian cancer. To participate in the call, interested parties may dial 833-816-1132 (Toll-Free/North America) or 412-317-0711

    7/29/25 8:30:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Leadership Updates

    Live Leadership Updates

    View All

    IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer

    Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology LAWRENCEVILLE, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the appointment of Douglas V. Faller, M.D., Ph.D., as chief medical officer, effective February 18, 2025. In this role, Dr. Faller will lead the company's clinical strategy including advancing its lead program IMNN-001 for the treatment of newly diagnosed advanced ovarian cancer, which is on track to enter a Phase 3 pivotal trial in the first quarter of 202

    2/10/25 8:05:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

    Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. as President and Chief Executive Officer, effective May 13, 2024. Dr. Lindborg has served on IMUNON's board of directors since 2021. Dr. Lindborg assumes the leadership of IMUNON at a pivotal time. Topline results from the Phase 2 OVATION 2 Stud

    5/8/24 8:00:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Accomplished pharmaceutical and biotechnology executive to lead IMUNON's clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Sebastien Hazard, M.D. as Chief Medical Officer, effective December 11, 2023. Dr. Hazard brings to IMUNON a strong background in building and leading clinical development organizations, most recently at Bicycle Therapeutics. He will report to IMUNON's President and Chief Executive Officer, Dr. Corinne Le

    12/11/23 8:30:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Imunon Inc.

    SCHEDULE 13G/A - Imunon, Inc. (0000749647) (Subject)

    8/13/25 6:29:02 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Imunon Inc.

    10-Q - Imunon, Inc. (0000749647) (Filer)

    8/5/25 9:00:44 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Imunon Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Imunon, Inc. (0000749647) (Filer)

    8/5/25 8:03:49 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Imunon Inc.

    SC 13G - Imunon, Inc. (0000749647) (Subject)

    11/14/24 5:37:34 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Imunon Inc.

    SC 13G/A - Imunon, Inc. (0000749647) (Subject)

    11/14/24 12:17:50 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Imunon Inc.

    SC 13G - Imunon, Inc. (0000749647) (Subject)

    8/5/24 11:53:32 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care